|
|
|
Volumn 33, Issue 2, 2006, Pages
|
|
Erythropoietin claims monitoring policy: implications for clinical practice.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
DRUG DERIVATIVE;
ERYTHROPOIETIN;
HEMOGLOBIN;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
ANEMIA;
BLOOD;
CHRONIC KIDNEY FAILURE;
DOCUMENTATION;
DRUG COST;
DRUG UTILIZATION;
ECONOMICS;
GOVERNMENT;
HUMAN;
INSURANCE;
METABOLISM;
ORGANIZATION AND MANAGEMENT;
PATIENT SELECTION;
POLICY;
PRACTICE GUIDELINE;
REIMBURSEMENT;
RENAL REPLACEMENT THERAPY;
REVIEW;
RISK FACTOR;
STANDARD;
TOTAL QUALITY MANAGEMENT;
UNITED STATES;
ANEMIA;
DOCUMENTATION;
DRUG COSTS;
DRUG UTILIZATION;
EPOETIN ALFA;
ERYTHROPOIETIN;
HEMATINICS;
HEMOGLOBINS;
HUMANS;
INSURANCE CLAIM REPORTING;
KIDNEY FAILURE, CHRONIC;
ORGANIZATIONAL POLICY;
PATIENT SELECTION;
PRACTICE GUIDELINES;
REIMBURSEMENT MECHANISMS;
RENAL DIALYSIS;
RISK FACTORS;
TOTAL QUALITY MANAGEMENT;
UNITED STATES;
UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES;
|
|
EID: 33646587024
PISSN: 1526744X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (4)
|
|
References (15)
|
